CHWY vs GIPL vs ZTS Stock Comparison

Chewy, Global Innovative Platforms and Zoetis Prices as of Oct 28, 2026 Peers: Industry group
CHWY Chewy, Inc.
$20.64 +10.8% 1M -39.6% 1Y
Market cap
$8.49B
P/E
31.0x
Revenue (TTM)
$13.07B
Div. yield
–
Packaged Foods Consumer Staples
2 wins
ZTS Zoetis Inc.
$77.79 +8.9% 1M -46.5% 1Y
Market cap
$32.85B
P/E
12.6x
Revenue (TTM)
$9.52B
Div. yield
0.03%
Animal Health Healthcare
7 wins

Head to Head

10 decided of 12

Zoetis leads on 7 of the 12 questions below (Zoetis 7, Chewy 2, Global Innovative Platforms 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCHWYGIPLZTSLeader
Larger companyMarket capitalisation $8.49B $24.88M $32.85B ZTS
Cheaper on earningsLower P/E, profitable companies only 31.0x -36.0x 12.6x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.2x — 13.3x ZTS
Faster revenue growthRevenue growth, trailing twelve months +5.9% — +1.5% CHWY
More profitableNet margin, trailing twelve months 2.1% -361.7% 27.5% ZTS
Better return on capitalReturn on invested capital — — 23.4% –
Less leveragedLower net debt / EBITDA 0.0x 0.4x 1.8x CHWY
Higher dividend yieldTrailing dividend yield 0.00% — 0.03% –
Better 1-year returnPrice return, last 12 months -39.6% -37.5% -46.5% GIPL
Better 5-year returnAnnualised price return, 5 years -22.9%/yr -36.9%/yr -18.5%/yr ZTS
Less volatileAnnualised volatility, 1 year 47.3% 270.9% 40.6% ZTS
Higher overall scoreMean of the five percentile scores vs peers 69/100 55/100 72/100 ZTS

Percentile Scorecard

CHWYGIPLZTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCHWYGIPLZTS
Valuation 57 #20 of 45 61 #244 of 625 88 #76 of 625
Growth 90 #5 of 42 27 #439 of 602 52 #290 of 602
Profitability 56 #18 of 40 39 #334 of 549 96 #23 of 549
Financial Health 61 #19 of 47 98 #12 of 654 34 #435 of 654
Shareholder Returns 80 #7 of 31 50 #184 of 367 90 #39 of 367
Overall 69 55 72
  • CHWY ranked among 48 companies in Branded Foods
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCHWYGIPLZTSSPY
1 month +10.8%0.0%+8.9% +0.9%
3 months -11.4%0.0%-0.2% +5.9%
6 months -20.5%-3.8%-31.7% +8.5%
Year to date -37.5%+354.5%-38.2% +13.3%
1 year -39.6%-37.5%-46.5% +12.4%
3 years +14.5%-52.4%-50.1% +88.1%
3 years, per year +4.6%-21.9%-20.7% +23.5%
5 years -72.8%-90.0%-64.0% +68.2%
5 years, per year -22.9%-36.9%-18.5% +11.0%
10 years —-79.2%+60.2% +263.4%
10 years, per year —-14.5%+4.8% +13.8%

Risk

MeasureCHWYGIPLZTSSPY
Volatility, 1Y 47.3%270.9%40.6% 12.7%
Downside volatility, 1Y 48.1%—49.2% 12.7%
Beta vs S&P 500, 1Y 0.782.260.52 1.00
Return / volatility, 1Y -0.84-0.14-1.14 0.98
Max drawdown, 5Y -81.2%-98.0%-72.0% -25.4%
From 52-week high -41.6%-49.5%-46.5% -0.9%
52-week high $35.37$0.99$145.41 $779.14
52-week low $17.51$0.11$69.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCHWYGIPLZTS
P/E now vs peer median 30.6xmedian 22.2x -36.0xmedian 17.4x 12.4xmedian 17.4x
P/S now vs peer median 0.6xmedian 0.7x 132.9xmedian 9.1x 3.4xmedian 9.1x
EV/EBITDA now vs peer median 17.5xmedian 12.2x -39.5xmedian 17.1x 9.7xmedian 17.1x
P/FCF now vs peer median 14.6xmedian 13.4x -32.5xmedian 19.0x 13.9xmedian 19.0x
P/B now vs peer median 22.4xmedian 1.6x 46.8xmedian 2.2x 10.2xmedian 2.2x
PEG now vs peer median 0.40median 0.56 -0.57median 0.34 1.32median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCHWYGIPLZTS
Revenue $13.07B $187.20K $9.52B
Gross profit $3.91B – $6.81B
Operating income $328.20M -$677.04K $3.59B
Net income $273.70M -$677.04K $2.62B
Free cash flow $568.10M -$766.04K $2.32B
R&D – $377.99K $722.00M
EPS (diluted) $0.67 $-0.02 $6.26
Cash & equivalents $611.00M $244.24K $1.48B
Total debt $591.70M $8.62K $9.05B
Shares (diluted) 410.10M 44.54M 417.70M
Enterprise value $5.77B $24.27M $24.70B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCHWYGIPLZTS
P/E 30.6x -36.0x 12.4x
P/FCF 14.6x -32.5x 13.9x
P/Operating cash flow 11.6x -35.0x 11.3x
P/S 0.6x 132.9x 3.4x
P/B 22.4x 46.8x 10.2x
P/Tangible book 37.5x 47.1x 14.4x
EV/EBITDA 17.5x -39.5x 9.7x
EV/EBIT 25.2x -36.4x 11.0x
EV/Revenue 0.6x 131.6x 4.2x
EV/FCF 14.5x -32.2x 17.1x
EV/Operating cash flow 11.5x -34.7x 13.9x
PEG (3Y EPS CAGR) 0.40 -0.57 1.32

Growth

14 metrics
MetricCHWYGIPLZTS
Revenue growth (1Y) 5.9% – 1.5%
Revenue CAGR (3Y) 6.4% – 5.0%
Gross profit growth (1Y) 7.6% – 1.8%
Gross profit CAGR (3Y) 8.5% – 5.7%
Operating income growth (1Y) 102.0% -20.9% -0.1%
Operating income CAGR (3Y) 139.1% -51.6% 5.2%
Net income growth (1Y) 81.1% -20.9% 0.6%
Net income CAGR (3Y) 73.8% -51.6% 5.7%
EPS growth (1Y) 89.2% -9.8% 7.7%
EPS CAGR (3Y) 76.8% 63.5% 9.4%
Operating cash flow growth (1Y) 17.3% 15.8% -4.6%
Operating cash flow CAGR (3Y) 10.9% -96.8% 12.4%
Free cash flow growth (1Y) 22.7% 9.2% 2.1%
Free cash flow CAGR (3Y) 18.6% -101.8% 21.7%

Profitability

14 metrics
MetricCHWYGIPLZTS
Gross margin 29.9% – 71.5%
EBITDA margin 3.6% -333.4% 42.8%
Operating margin 2.5% -361.7% 37.7%
Pretax margin 2.7% -361.7% 34.4%
Net margin 2.1% -361.7% 27.5%
FCF margin 4.3% -409.2% 24.3%
Operating cash flow margin 5.5% -379.8% 29.8%
Return on equity 68.9% -120.8% 82.0%
Return on assets 7.8% -119.7% 17.3%
Return on invested capital – – 23.4%
Return on capital employed 24.9% -121.4% 27.5%
Asset turnover 3.7x 0.3x 0.6x
Cash conversion (OCF / net income) 2.6x 1.1x 1.1x
Stock comp / revenue 2.3% – 1.0%

Financial Health

11 metrics
MetricCHWYGIPLZTS
Debt / assets 15.8% 1.0% 60.0%
Debt / equity 1.6x 0.0x 2.9x
Net debt / EBITDA 0.0x 0.4x 1.8x
Debt / FCF 1.0x 0.0x 3.9x
Liabilities / assets 90.1% 1.4% 79.1%
Equity / assets 9.9% 98.6% 20.9%
Interest coverage – – 15.1x
Current ratio 0.8x 34.7x 3.1x
Quick ratio 0.4x 33.2x 1.6x
Cash ratio 0.3x 31.3x 0.8x
Altman Z-score 4.70 1,908 4.74

Shareholder Returns

7 metrics
MetricCHWYGIPLZTS
Dividend yield – – 2.7%
Net buyback yield 6.2% -3.2% 11.3%
Shareholder yield 6.2% -3.2% 14.0%
Payout ratio (earnings) – – 34.0%
Payout ratio (FCF) – – 38.4%
Dividend growth (1Y) – – 6.1%
Dividend CAGR (3Y) – – 10.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCHWYGIPLZTS
Forward P/E 27.2xFY2026 – 13.3xFY2026
EPS, next fiscal year $0.76FY2026 – $5.86FY2026
EPS growth, next FY +46.2%FY2026 – -8.6%FY2026
EPS growth, the year after +47.4% – +13.0%
Revenue, next fiscal year $12.87BFY2026 – $9.57BFY2026
Revenue growth, next FY +2.1%FY2026 – +1.0%FY2026
Revenue growth, the year after +5.5% – -7.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCHWYGIPLZTS
Held by institutions 100.0% – 94.7%
Institutions holding 511 – 1,417
Change in shares held, QoQ -0.4% – -2.6%
Institutions buying 277 – 674
Institutions selling 155 – 582
Buyers to sellers 1.79 – 1.16

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CHWYGIPLZTS
CHWY 1.00 0.01 0.20
GIPL 0.01 1.00 0.02
ZTS 0.20 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CHWY, GIPL and ZTS?

Zoetis (ZTS) is the largest by market capitalisation: Chewy (CHWY) $8.49B, Global Innovative Platforms (GIPL) $24.88M, Zoetis (ZTS) $32.85B.

Which stock is cheaper, CHWY, GIPL and ZTS?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Chewy (CHWY) 31.0x, Global Innovative Platforms (GIPL) -36.0x, Zoetis (ZTS) 12.6x). On next year's consensus earnings, Zoetis (ZTS) is cheapest (Chewy (CHWY) 27.2x, Zoetis (ZTS) 13.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Chewy (CHWY) grew revenue fastest over the trailing twelve months: Chewy (CHWY) +5.9%, Zoetis (ZTS) +1.5%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Chewy (CHWY) 2.1%, Global Innovative Platforms (GIPL) -361.7%, Zoetis (ZTS) 27.5%).

Which stock has performed better?

Over the past year Global Innovative Platforms (GIPL) returned the most: Chewy (CHWY) -39.6%, Global Innovative Platforms (GIPL) -37.5%, Zoetis (ZTS) -46.5%. Over five years, Zoetis (ZTS) compounded fastest (Chewy (CHWY) -22.9%/yr, Global Innovative Platforms (GIPL) -36.9%/yr, Zoetis (ZTS) -18.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Chewy (CHWY) 0.00%, Zoetis (ZTS) 0.03%. Chewy (CHWY) and Global Innovative Platforms (GIPL) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Chewy (CHWY) 47.3%, Global Innovative Platforms (GIPL) 270.9%, Zoetis (ZTS) 40.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CHWY, GIPL and ZTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.